GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

compound 27 [WO2016008433]   Click here for help

GtoPdb Ligand ID: 13919

Synonyms: clifutinib | compound 9e [PMID: 40213868]
Compound class: Synthetic organic
Comment: This is a tyrosine kinase inhibitor claimed in patent WO2016008433A1, in which it is proposed as a fms related receptor tyrosine kinase 3 (FLT3 inhibitor) with anti-leukemic potential [1]. It appears be the structure for HEC Pharma's FLT3 inhibitor named clifutinib (not an official INN) which is reported in [2].
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 6
Hydrogen bond donors 2
Rotatable bonds 10
Topological polar surface area 84.42
Molecular weight 502.61
XLogP 3.33
No. Lipinski's rules broken 1

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

SMILES / InChI / InChIKey
Click here for help
Canonical SMILES CC(C)(C)C1=CC(=NO1)NC(=O)NC2=CC=C(C#CC3=CC=C(C=C3)OCCCN4CCOCC4)C=C2
Isomeric SMILES CC(C)(C)C1=CC(NC(=O)NC2=CC=C(C=C2)C#CC3=CC=C(OCCCN4CCOCC4)C=C3)=NO1
InChI InChI=1S/C29H34N4O4/c1-29(2,3)26-21-27(32-37-26)31-28(34)30-24-11-7-22(8-12-24)5-6-23-9-13-25(14-10-23)36-18-4-15-33-16-19-35-20-17-33/h7-14,21H,4,15-20H2,1-3H3,(H2,30,31,32,34)
InChI Key DWZXYPARIPYQKS-UHFFFAOYSA-N

Generated using the Chemistry Development Kit (CDK) (Willighagen EL et al. Journal of Cheminformatics vol. 9:33. 2017, doi:10.1186/s13321-017-0220-4; https://cdk.github.io/)

References
1. Cheng C, Zhang Y, Liu B, Long B, Chern Y, Cheng Z. (2016)
ubstituted urea derivatives and pharmaceutical uses thereof.
Patent number: WO2016008433A1. Assignee: Sunshine Lake Pharma Co., Ltd.. Priority date: 19/07/2015. Publication date: 21/01/2016.
2. Liu B, Kang N, Yang F, Zhang W, Yan X, Wang H, Bai S, Cheng CC, Xu J, Hu W et al.. (2025)
Discovery of FLT3-ITD Inhibitor Clifutinib: A Novel Biphenylacetylene Urea Derivative in Clinical Trials for the Treatment of Relapsed/Refractory FLT3-ITD+ Acute Myeloid Leukemia.
J Med Chem, 68 (8): 7955-7972. [PMID:40213868]